N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)methanesulfonamide | 1044143-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)methanesulfonamide
• 英文别名: N-[4-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]phenyl]methanesulfonamide
• CAS: 1044143-59-0
• 化学式: C₁₉H₂₄N₆O₂S
• 分子量: 400.505
• InChiKey: BOVLFNSGFMRUHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-氯丙烷 、 N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)methanesulfonamide 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[4-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]phenyl]-N-propan-2-ylmethanesulfonamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)

  摘要：

  A novel class of pyrazolopyrimidine-sulfonamides was discovered as selective dual inhibitors of aurora kinase A (AKA) and cyclin-dependent kinase 1 (CDK1). These inhibitors were originally designed based on an early lead (compound I). SAR development has led to the discovery of potent inhibitors with single digit nM IC(50)s towards both AKA and CDK1. An exemplary compound 1a has demonstrated good efficacy in an HCT116 colon cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.129
• 作为产物：
  描述：

  1-环庚基-6-(甲基硫代)-1H-吡唑并[3,4-d]嘧啶 在 Oxone 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 氯仿 、 水 、 二甲基亚砜 为溶剂， 生成 N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)methanesulfonamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)

  摘要：

  A novel class of pyrazolopyrimidine-sulfonamides was discovered as selective dual inhibitors of aurora kinase A (AKA) and cyclin-dependent kinase 1 (CDK1). These inhibitors were originally designed based on an early lead (compound I). SAR development has led to the discovery of potent inhibitors with single digit nM IC(50)s towards both AKA and CDK1. An exemplary compound 1a has demonstrated good efficacy in an HCT116 colon cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.129

文献信息

• Modulators of Mitotic Kinases
  申请人：Kasibhatla Srinivas Rao

  公开号：US20110281821A9

  公开（公告）日：2011-11-17

  The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.

  本发明涉及公式（I）的化合物，其包括多晶形、对映异构体、立体异构体、溶剂化物、N-氧化衍生物或其药学上可接受的盐：公式（I），其具有对参与细胞有丝分裂的一个或多个蛋白激酶具有抑制作用。
• 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES
  申请人：Biogen Idec MA, Inc.

  公开号：EP2108020A2

  公开（公告）日：2009-10-14
• [EN] MODULATORS OF MITOTIC KINASES<br/>[FR] MODULATEURS DE KINASES MITOTIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2008094602A2

  公开（公告）日：2008-08-07

  [EN] The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide derivatve, or a pharmaceutically acceptable salt thereof: Formula (I); which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.
  [FR] L'invention concerne des composés représentés par la formule (I), un promédicament, un polymorphe, un tautomère, un énantiomère, un stéréoisomères, un solvate, un N-oxyde ou un sel pharmaceutiquement acceptable de ces composés : formule (I) qui possèdent un effet inhibiteur sur une ou plusieurs protéines kinases impliquées dans la mitose cellulaire.